Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SRP4693

Sigma-Aldrich

Apolipoprotein A−I human

recombinant, expressed in E. coli, ≥97% (SDS-PAGE), ≥97% (HPLC)

Sinônimo(s):

APOA1, Apo-AI, Apolipoprotein A-I, C117399, MGC117399

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Número CAS:
Código UNSPSC:
12352202
NACRES:
NA.32

fonte biológica

human

recombinante

expressed in E. coli

Ensaio

≥97% (HPLC)
≥97% (SDS-PAGE)

Formulário

lyophilized

peso molecular

~28 kDa

embalagem

pkg of 100 μg

condição de armazenamento

avoid repeated freeze/thaw cycles

Impurezas

endotoxin, tested

nº de adesão NCBI

nº de adesão UniProt

Condições de expedição

wet ice

temperatura de armazenamento

−20°C

Informações sobre genes

human ... ApoA1(335)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

ApoA-I (apolipoprotein A-I) is a 29.0kDa protein produced in the liver and intestine, and secreted as the predominant constituent of nascent high-density lipoprotein (HDL) particle. Recombinant human ApoA-I is a 28.2kDa protein of 244 amino acid residues.
ApoA-I, which is found exclusively in HDL, has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is though to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.

Aplicação

Apolipoprotein A-I human has been used in the cholesterol efflux assay.

Ações bioquímicas/fisiológicas

ApoA-I (apolipoprotein A-I), which is found exclusively in HDL (high-density lipoprotein), has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is thought to inhibit atherogenesis. For this reason HDL is also known as the "good cholesterol." The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases. Changes in the level of serum apoA-I may serve as a prognostic marker for non-metastatic nasopharyngeal carcinoma. Low levels of apoA-I in the plasma is linked to hyperhomocysteinemia.

forma física

Sterile filtered and Lyophilized without additives.

Nota de preparo

Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.

Reconstituição

Reconstitute in water to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers and store at 4 °C for 1 week or –20 °C for future use.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Huairui Shi et al.
Scientific reports, 6, 20154-20154 (2016-01-30)
Lanatoside C's impact on atherosclerosis is poorly understood. The present study was conducted to determine whether lanatoside C affects the development of atherosclerosis in apolipoprotein E-deficient (ApoE(-/-)) mice. ApoE(-/-) mice were administered either phosphate-buffered saline (PBS) containing 0.1% DMSO (the
Yuanyuan Li et al.
Arteriosclerosis, thrombosis, and vascular biology, 39(8), 1574-1587 (2019-07-12)
To determine the role of hepatic FOXA3 (forkhead box A3) in lipid metabolism and atherosclerosis. Approach and Results: Hepatic FOXA3 expression was reduced in diabetic or high fat diet-fed mice or patients with nonalcoholic steatohepatitis. We then used adenoviruses to
ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I.
Gelissen IC
Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 534-540 (2006)
Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma.
Luo XL, et al.
Oncotarget, 6, 44037-44048 (2015)
Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration.
Jolley CD, et al.
Journal of Lipid Research, 39, 2143-2149 (1998)

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica